Stoute, José A <br/><br/>
Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya.  [electronic resource] 

 -  Vaccine  Jan 2007 
 - 176-84 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, Non-P.H.S. 
<br/><br/><label>ISSN: </label>0264-410X 
<br/><br/><label>Standard No.: </label>10.1016/j.vaccine.2005.11.037  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adjuvants, Immunologic--administration & dosage<br/>Adult<br/>Animals<br/>Antibodies, Protozoan--blood<br/>Double-Blind Method<br/>Drug Combinations<br/>Female<br/>Humans<br/>Kenya<br/>Lipid A--administration & dosage<br/>Malaria Vaccines--administration & dosage<br/>Malaria, Falciparum--immunology<br/>Male<br/>Merozoite Surface Protein 1--chemistry<br/>Middle Aged<br/>Plasmodium falciparum--immunology<br/>Saponins--administration & dosage<br/>Treatment Outcome